KEY TAKEAWAY: As big pharma gets bigger, the one challenge they have mastered is the reduction in administrative burdens they place on managers and employees.
Continue readingBig pharma: its own worst enemy
Reply
Author Archives: Richard Meyer
Drug pricing ads: A pharma PR nightmare
KEY TAKEAWAY: Drug pricing in pharma DTC ads is not going to affect the prices of drugs. The list price doesn’t mean a damn thing to patients who have any health insurance. However, a lawsuit against pricing in ads is going to a PR nightmare for pharma companies.
Continue readingStop blaming pharma for your bad habits
KEY SUMMARY: The idea that pharma “likes to keep people sick” is an excuse for poor lifestyle choices. The percentage of people who are overweight or obese soared from 22 percent in 1994 to 42 percent in 2016, nearly doubling. Obesity impacts where consumers spend their money. An individual with a body mass index (BMI) that’s considered “obese” spends 42 percent more on direct health care costs than adults who are a healthy weight.
Continue readingPeople don’t make healthcare decisions based on a TV commercial
KEY IDEA: Online metrics can paint an important picture for DTC marketers but either brand teams don’t have the headcount to adequately leverage insights or they are too focused on TV.
Continue readingQuant Research – Online health seekers need help
KEY TAKEAWAY: Online health seekers feel overwhelmed with the quantity of online health information and often don’t know who to trust on social media to help them make informed and educated decisions. Pharma websites are often a stop on the search but don’t have enough information to help online health seekers make a final decision.
Continue readingThe promise of accelerated approval of cancer drugs
KEY TAKEAWAY: Few cancer drugs approved via the accelerated FDA approval pathway were judged to have verified benefits based on improvement in survival reported in confirmatory trials.
Continue readingMore proof that it’s about profits not patients.
IN SUMMARY: A study, in the journal JAMA Network Open, found a substantial industry-wide rise in insurer and out-of-pocket costs for top-selling, brand-name prescription drugs, highlighting one of the foremost problems in health care today: unimpeded price increases in the pharmaceutical market. Pharma companies are daring the government to intervene in the drug pricing debate.
Continue reading